37 related articles for article (PubMed ID: 26902503)
1. Predicting steady-state endoxifen plasma concentrations in breast cancer patients by CYP2D6 genotyping or phenotyping. Which approach is more reliable?
Gusella M; Pasini F; Corso B; Bertolaso L; De Rosa G; Falci C; Modena Y; Barile C; Da Corte Z D; Fraccon A; Toso S; Cretella E; Brunello A; Modonesi C; Segati R; Oliani C; Minicuci N; Padrini R;
Pharmacol Res Perspect; 2020 Oct; 8(5):e00646. PubMed ID: 32813313
[TBL] [Abstract][Full Text] [Related]
2. Impact of Pregnancy and Vitamin A Supplementation on CYP2D6 Activity.
Amaeze OU; Czuba LC; Yadav AS; Fay EE; LaFrance J; Shum S; Moreni SL; Mao J; Huang W; Isoherranen N; Hebert MF
J Clin Pharmacol; 2023 Mar; 63(3):363-372. PubMed ID: 36309846
[TBL] [Abstract][Full Text] [Related]
3. Impact of Viloxazine Extended-Release Capsules (Qelbree
Wang Z; Liranso T; Maldonado-Cruz Z; Kosheleff AR; Nasser A
Clin Drug Investig; 2024 May; 44(5):303-317. PubMed ID: 38598106
[TBL] [Abstract][Full Text] [Related]
4. Investigation of the Differences in the Pharmacokinetics of CYP2D6 Substrates, Desipramine, and Dextromethorphan in Healthy African Subjects Carrying the Allelic Variants CYP2D6*17 and CYP2D6*29, When Compared with Normal Metabolizers.
Marasanapalle VP; Masimirembwa C; Sivasubramanian R; Sayyed S; Weinzierl-Hinum A; Mehta D; Kapungu NN; Kanji C; Thelingwani R; Zack J
J Clin Pharmacol; 2024 May; 64(5):578-589. PubMed ID: 37803948
[TBL] [Abstract][Full Text] [Related]
5. Effects of Maribavir on P-Glycoprotein and CYP2D6 in Healthy Volunteers.
Song IH; Ilic K; Murphy J; Lasseter K; Martin P
J Clin Pharmacol; 2020 Jan; 60(1):96-106. PubMed ID: 31385617
[TBL] [Abstract][Full Text] [Related]
6. Effect of isotretinoin on CYP2D6 and CYP3A activity in patients with severe acne.
Zhao Y; Vary JC; Yadav AS; Czuba LC; Shum S; LaFrance J; Huang W; Isoherranen N; Hebert MF
Br J Clin Pharmacol; 2024 Mar; 90(3):759-768. PubMed ID: 37864393
[TBL] [Abstract][Full Text] [Related]
7. Nutrimetric Validation of Solanidine as Dietary-Derived CYP2D6 Activity Marker In Vivo.
Müller JP; Sarömba J; Ziegler P; Tremmel R; Rengelshausen J; Schaeffeler E; Just KS; Schwab M; Kraus T; Stingl JC
Clin Pharmacol Ther; 2024 Feb; 115(2):309-317. PubMed ID: 37971251
[TBL] [Abstract][Full Text] [Related]
8. CYP2D6 Metabolism in Frail Elderly Compared to Non-Frail Elderly: A Pilot Feasibility Study.
Opdam FL; Modak AS; Mooijaart SP; Louwerens M; de Waal MW; Gelderblom H; Guchelaar HJ
Drugs Aging; 2015 Dec; 32(12):1019-27. PubMed ID: 26597400
[TBL] [Abstract][Full Text] [Related]
9. Detection of an endogenous urinary biomarker associated with CYP2D6 activity using global metabolomics.
Tay-Sontheimer J; Shireman LM; Beyer RP; Senn T; Witten D; Pearce RE; Gaedigk A; Gana Fomban CL; Lutz JD; Isoherranen N; Thummel KE; Fiehn O; Leeder JS; Lin YS
Pharmacogenomics; 2014 Dec; 15(16):1947-62. PubMed ID: 25521354
[TBL] [Abstract][Full Text] [Related]
10. Validation of a bupropion, dextromethorphan, and omeprazole cocktail for simultaneous phenotyping of cytochrome P450 2B11, 2D15, and 3A12 activities in dogs.
Martinez SE; Jimenez TEP; Court MH
Am J Vet Res; 2024 May; ():1-10. PubMed ID: 38718826
[TBL] [Abstract][Full Text] [Related]
11. Terbinafine-associated inhibition of dextromethorphan metabolism in Chinese subjects.
Cai WM; Chen B; Ling SS; Zhang YD
Br J Clin Pharmacol; 2001 Jan; 51(1):107-8. PubMed ID: 11167673
[No Abstract] [Full Text] [Related]
12. CYP2D6 Is Inducible by Endogenous and Exogenous Corticosteroids.
Farooq M; Kelly EJ; Unadkat JD
Drug Metab Dispos; 2016 May; 44(5):750-7. PubMed ID: 26965986
[TBL] [Abstract][Full Text] [Related]
13. Practical interpretation of CYP2D6 haplotypes: Comparison and integration of automated and expert calling.
Ruaño G; Kocherla M; Graydon JS; Holford TR; Makowski GS; Goethe JW
Clin Chim Acta; 2016 May; 456():7-14. PubMed ID: 26908082
[TBL] [Abstract][Full Text] [Related]
14. CYP2D6 genotype and phenotyping by determination of dextromethorphan and metabolites in serum of healthy controls and of patients under psychotropic medication.
Köhler D; Härtter S; Fuchs K; Sieghart W; Hiemke C
Pharmacogenetics; 1997 Dec; 7(6):453-61. PubMed ID: 9429230
[TBL] [Abstract][Full Text] [Related]
15. The impact of
Jin Y; Zhang S; Hu P; Zheng X; Guan X; Chen R; Zhang S
Front Pharmacol; 2022; 13():940510. PubMed ID: 36110554
[No Abstract] [Full Text] [Related]
16.
Chen R; Zheng X; Hu P
Front Pharmacol; 2017; 8():239. PubMed ID: 28512430
[No Abstract] [Full Text] [Related]
17. Alternative methods for CYP2D6 phenotyping: comparison of dextromethorphan metabolic ratios from AUC, single point plasma, and urine.
Chen R; Wang H; Shi J; Hu P
Int J Clin Pharmacol Ther; 2016 May; 54(5):330-6. PubMed ID: 26902503
[TBL] [Abstract][Full Text] [Related]
18. Application of a physiologically based pharmacokinetic model for the evaluation of single-point plasma phenotyping method of CYP2D6.
Chen R; Rostami-Hodjegan A; Wang H; Berk D; Shi J; Hu P
Eur J Pharm Sci; 2016 Sep; 92():131-6. PubMed ID: 27412587
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
